Efficacy and Safety of Denosumab versus Zoledronic Acid in the Treatment of Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Comparative Study
Authors' conclusion
Denosumab provides Ca-lowering efficacy comparable to that of ZA, with fewer acute adverse events, and may serve as a useful alternative, particularly for patients with impaired renal function.
Study context
- Population
- Patients with PHPT and hypercalcemia
- Participants
- 90 patients
- Exposure
- Denosumab vs zoledronic acid
- Denosumabn = 45
- Zoledronic acid (ZA)n = 45reference
- Outcome
- Serum Ca levels
- Follow-up
- Weeks 2-4
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Serum Ca
P = 0.74
Observational data: associations, not effects.
Further findings
Reduction in serum Ca · day 2 · greater initial reduction with ZA
P < 0.001
Serum calcium (Ca) after week 1
- No significant between-group differences after week 1
Safety
Adverse events · more frequent with ZA, largely driven by fever
P < 0.001
- Hypocalcemia · within 4 weeks · similar between groups
- P = 0.50
- Renal function (eGFR) · 1 week · no significant difference
- P = 0.68
Original publication
Efficacy and Safety of Denosumab versus Zoledronic Acid in the Treatment of Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Comparative Study. Endocr Pract. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →